The antiapoptotic Bcl-2 family proteins play critical roles in resistance to chemotherapy in acute myeloid leukaemia (AML). The Bcl-2-selective inhibitor 
| INTRODUCTION
Despite substantially enhanced understanding of the biology of acute myeloid leukaemia (AML), standard chemotherapy (cytarabine plus an anthracycline, e.g. daunorubicin) and bone marrow transplant have remained the main treatment option for patients with AML over the course of the last four decades. This lack of change in standard of care has led to a meagre improvement in AML survival compared to other leukaemia types. Although many fit patients respond initially to standard therapy, survival rates remain low because of disease relapse. Leukaemic stem cells (LSCs), and our inability to target them, are believed to be responsible for AML relapse. 1 Bcl-2 is overexpressed in bulk AML cells and LSCs, making it a promising therapeutic target for the treatment of AML.
2 Anti-apoptotic Bcl-2 family proteins (e.g., Bcl-2, Bcl-xL, and Mcl-1) sequester proapoptotic Bcl-2 family proteins, such as Bim, to prevent induction of apoptosis. 3 The Bcl-2 family has been found to be dysregulated in AML, with increases in Bcl-2, Bcl-xL, and/or Mcl-1 expression associated with chemotherapy resistance and poor prognoses. 2, [4] [5] [6] [7] Mcl-1 was previously shown to be necessary to inhibit Bak and Bax activation. [8] [9] [10] Thus, targeting the anti-apoptotic Bcl-2 family proteins represent a promising strategy for the treatment of AML. Although inhibitors of this family have been promising, inhibition of Bcl-xL has been associated with platelet death and subsequent thrombocytopenia, 5 which has sparked interest in the Bcl-2-selective inhibitor ABT-199 (Venetoclax). Its excellent antileukaemic activity against chronic lymphocytic leukaemia led to FDA approval in April 2016. Our group and others have reported that ABT-199 has promising activity against preclinical models of AML and other cancers. [11] [12] [13] [14] [15] [16] [17] Results of a phase II clinical trial have shown that ABT-199 has promising clinical activity compared to current alternatives, but relapse remains a concern. 18, 19 Combinations such as ABT-199 with decitabine or azacitidine can help induce remission but lack improvement in overall survival. 20 Thus, new therapeutic combinations involving ABT-199 are urgently needed to eradicate bulk AML cells and LSCs responsible for relapse.
Bcl-2 sequesters Bim, preventing Bim from inducing apoptosis.
We have shown that the small molecule inhibitor ABT-199 can disrupt this interaction in AML. 21 However, from Dharmacon (Lafayette, CO, USA). Lentivirus production and transduction were carried out as previously described. 46 Briefly, TLA-HEK293T cells were transfected with pMD-VSV-G, delta 8.2, and lentiviral shRNA or Precision LentiORF constructs using Lipofectamine and Plus reagents (Life Technologies, Carlsbad, CA, USA)
according to the manufacturer's instructions. Virus containing culture medium was harvested 48 hours post transfection. Cells were transduced overnight using 1 mL of virus supernatant and 4 μg of polybrene and then cultured for an additional 48 hours prior to selection with puromycin or blasticidin.
| CRISPR knockdown
The lentiCRISPRv2 plasmid was a gift from Feng Zhang at the Broad Institute of MIT and Harvard (Addgene plasmid #52961). Guide
RNAs were designed using the CRISPR design tool (http://crispr.
mit.edu). The NTC and Mcl-1 vectors were generated using Feng Zhang's protocol, which is available on Addgene's website (www.add gene.org). Lentivirus production and transduction were carried out as described above in "shRNA Knockdown," except that psPAX2 (gift from Didier Trono at the Swiss Institute of Technology, Addgene plasmid #12260) was used instead of delta 8.2. 
| Colony forming assay

| RT-PCR
Total RNA was extracted using TRIzol (Thermo Fisher Scientific) and cDNAs were prepared from 2 μg total RNA using random hexamer primers and a RT-PCR Kit (Thermo Fisher Scientific), and then purified using the QIAquick PCR Purification Kit (Qiagen, Germantown, MD, USA), as described previously. 
| MTT assays
Sigma-Aldrich) assays were performed as previously described. 36, 43, 48 Human PMNC samples were treated with variable concentrations of
ABT-199 and/or KPT-330 for 72 hours. For each PMNC sample, the MTT assay was performed once due to limited sample. 
| Statistical analysis
| DISCUSSION
ABT-199 has demonstrated clinical activity, though as a monotherapy relapse occurred in a mere 2.5 months and in combination with decitabine or azacitidine there was no significant improvement in overall survival rate compared to decitabine or azacitidine alone. [18] [19] [20] Therefore, new combination approaches for are necessary to improve the long-term survival of AML patients.
In this study, we show that KPT-330 is able to overcome ABT- However, the combination does appear to synergize in normal PMNC cells ex vivo, suggesting that toxicity could be a concern.
Further in vitro mechanistic studies and in vivo testing in AML mouse models is warranted to determine efficacy against LSCs as well as tolerability. 
